Type III Interferons in Antiviral Defenses at Barrier Surfaces

Trends in Immunology

Volumn 39, Issue 10, 2018, Pages 848-858

  Wells, Alexandra I ^a,b   Coyne, Carolyn B ^a,b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

Author keywords

barrier surfaces; innate immunity; interferon; placenta

Indexed keywords

INTERFERON; INTERFERON LAMBDA; UNCLASSIFIED DRUG; INTERFERON TYPE III;

ANTIVIRAL ACTIVITY; BLOOD BRAIN BARRIER; BLOOD PLACENTA BARRIER; CYTOKINE PRODUCTION; GASTROINTESTINAL EPITHELIUM; GASTROINTESTINAL TRACT; HUMAN; INFECTION CONTROL; NONHUMAN; PERMEABILITY BARRIER; PLACENTA; PROTEIN FUNCTION; PROTEIN INDUCTION; RESPIRATORY EPITHELIUM; RESPIRATORY SYSTEM; REVIEW; SIGNAL TRANSDUCTION; VIRUS INFECTION; ANIMAL; FEMALE; FUNCTIONS OF THE SKIN AND ITS APPENDAGES; IMMUNOLOGY; METABOLISM; PREGNANCY;

ANIMALS; BLOOD-BRAIN BARRIER; FEMALE; GASTROINTESTINAL TRACT; HUMANS; INTERFERONS; PLACENTA; PREGNANCY; RESPIRATORY SYSTEM; SKIN PHYSIOLOGICAL PHENOMENA; VIRUS DISEASES;

EID: 85053145909     PISSN: 14714906     EISSN: 14714981     Source Type: Journal    
DOI: 10.1016/j.it.2018.08.008     Document Type: Review

References (77)

1. Kay, H., et al. The Placenta: From Development to Disease. 2011, Wiley-Blackwell.
2. Cornick, S., et al. Roles and regulation of the mucus barrier in the gut. Tissue Barriers, 3, 2015, e982426.
3. Delorme-Axford, E., Coyne, C.B., The actin cytoskeleton as a barrier to virus infection of polarized epithelial cells. Viruses 3 (2011), 2462–2477.
4. Schneider, W.M., et al. Interferon-stimulated genes: a complex web of host defenses. Annu. Rev. Immunol. 32 (2014), 513–545.
5. Isaacs, A., Lindenmann, J., Virus interference. I. The interferon. J. Interferon Res. 7 (1987), 429–438.
6. Hardy, M.P., et al. Characterization of the type I interferon locus and identification of novel genes. Genomics 84 (2004), 331–345.
7. Henco, K., et al. Structural relationship of human interferon alpha genes and pseudogenes. J. Mol. Biol. 185 (1985), 227–260.
8. Díaz, M.O., et al. Structure of the human type-I interferon gene cluster determined from a YAC clone contig. Genomics 22 (1994), 540–552.
9. Kotenko, S.V., et al. IFN-λs mediate antiviral protection through a distinct class II cytokine receptor complex. Nat. Immunol. 4 (2003), 69–77.
10. Sheppard, P., et al. Il-28, IL-29 and their class II cytokine receptor IL-28R. Nat. Immunol. 4 (2003), 63–68.
11. Prokunina-Olsson, L., et al. A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus. Nat. Genet. 45 (2013), 164–171.
12. Hamming, O.J., et al. Interferon lambda 4 signals via the IFNλ receptor to regulate antiviral activity against HCV and coronaviruses. EMBO J. 32 (2013), 3055–3065.
13. Wack, A., et al. Guarding the frontiers: the biology of type III interferons. Nat. Immunol. 16 (2015), 802–809.
14. Kotenko, S.V., Durbin, J.E., Contribution of type III interferons to antiviral immunity: location, location, location. J. Biol. Chem. 292 (2017), 7295–7303.
15. Sabat, R., IL-10 family of cytokines. Cytokine Growth Factor Rev. 21 (2010), 315–324.
16. Walter, M.R., The molecular basis of IL-10 function: from receptor structure to the onset of signaling. Curr. Top. Microbiol. Immunol. 380 (2014), 191–212.
17. Sommereyns, C., et al. IFN-lambda is expressed in a tissue-dependent fashion and primarily acts on epithelial cells in vivo. PLoS Pathog., 4, 2008, e1000017.
18. Kelly, A., et al. Immune cell profiling of IFN-lambda response shows pDCs express highest level of IFN-lR1 and are directly responsive via the JAK–STAT pathway. J. Interferon Cytokine Res. 36 (2016), 671–680.
19. Blazek, K., et al. IFN-λ resolves inflammation via suppression of neutrophil infiltration and IL-1β production. J. Exp. Med. 212 (2015), 845–853.
20. Broggi, A., et al. IFN-λ suppresses intestinal inflammation by non-translational regulation of neutrophil function. Nat. Immunol. 18 (2017), 1084–1093.
21. Uematsu, S., Akira, S., Toll-like receptors and innate immunity. J. Mol. Med. 84 (2006), 712–725.
22. Durbin, R.K., et al. Interferon induction and function at the mucosal surface. Immunol. Rev. 255 (2013), 25–39.
23. Maniatis, T., et al. Structure and function of the interferon-beta enhanceosome. Cold Spring Harb. Symp. Quant. Biol. 63 (1998), 609–620.
24. Thomson, S.J.P., et al. The role of transposable elements in the regulation of IFN-lambda1 gene expression. Proc. Natl. Acad. Sci. U. S. A. 106 (2009), 11564–11569.
25. Seth, R.B., et al. Antiviral innate immunity pathways. Cell Res., 16, 2006.
26. De Weerd, N.A., Nguyen, T., The interferons and their receptors-distribution and regulation. Immunol. Cell Biol. 90 (2012), 483–491.
27. Ingle, H.I., et al. Distinct effects of type I and III interferons on enteric viruses. Viruses 10 (2018), 1–23.
28. Bolen, C.R., et al. Dynamic expression profiling of type I and type III interferon-stimulated hepatocytes reveals a stable hierarchy of gene expression. Hepatology 59 (2014), 1262–1272.
29. Selvakumar, T.A., et al. Identification of a predominantly interferon-λ-induced transcriptional profile in murine intestinal epithelial cells. Front. Immunol., 8, 2017, 1302.
30. Bhushal, S., et al. Cell polarization and epigenetic status shape the heterogeneous response to type III interferons in intestinal epithelial cells. Front. Immunol., 8, 2017, 671.
31. Kojima, T., et al. Regulation of tight junctions in upper airway epithelium. Biomed. Res. Int. 2013 (2012), 1–11.
32. Yaghi, A., Dolovich, M., Airway epithelial cell cilia and obstructive lung disease. Cells 5 (2016), 1–19.
33. Jewell, N.A., et al. Lambda interferon is the predominant interferon induced by influenza A virus infection in vivo. J. Virol. 84 (2010), 11515–11522.
34. Mordstein, M., et al. Lambda interferon renders epithelial cells of the respiratory and gastrointestinal tracts resistant to viral infections. J. Virol. 84 (2010), 5670–5677.
35. Andreakos, E., et al. Interferon-λs: front-line guardians of immunity and homeostasis in the respiratory tract. Front. Immunol. 8 (2017), 1–7.
36. Davidson, S., et al. IFNλ is a potent anti-influenza therapeutic without the inflammatory side effects of IFNα treatment. EMBO Mol. Med. 8 (2016), 1099–1112.
37. Fox, J.M., et al. Interferon lambda upregulates IDO1 expression in respiratory epithelial cells after influenza virus infection. J. Interferon Cytokine Res. 35 (2015), 554–562.
38. Iwasaki, A., Pillai, P.S., Innate immunity to influenza virus infection. Nat. Rev. Immunol. 14 (2014), 315–328.
39. Wang, J., et al. Human alveolar type II cells secrete antiviral IL-29 (IFN-λ1) in response to influenza A infection. J. Immunol. 182 (2009), 1296–1304.
40. Travar, M., et al. Type I, II, and III interferons: regulating immunity to Mycobacterium tuberculosis infection. Arch. Immunol. Ther. Exp. 64 (2016), 19–31.
41. Villenave, R., et al. Induction and antagonism of antiviral responses in respiratory syncytial virus-infected pediatric airway epithelium. J. Virol. 89 (2015), 12309–12318.
42. Galani, I.E., et al. Interferon-λ mediates non-redundant front-line antiviral protection against influenza virus infection without compromising host fitness. Immunity 46 (2017), 875–890.
43. Mordstein, M., et al. Interferon-λ contributes to innate immunity of mice against influenza A virus but not against hepatotropic viruses. PLoS Pathog. 4 (2008), 1–7.
44. Sambuy, Y., et al. The Caco-2 cell line as a model of the intestinal barrier: influence of cell and culture-related factors on Caco-2 cell functional characteristics. Cell Biol. Toxicol. 21 (2005), 1–26.
45. Kotredes, K.P., et al. The protective role of type I interferons in the gastrointestinal tract. Front. Immunol. 8 (2017), 1–10.
46. Pott, J., et al. IFN-λ determines the intestinal epithelial antiviral host defense. Proc. Natl. Acad. Sci. U. S. A. 108 (2011), 7944–7949.
47. Baldridge, M.T., et al. Expression of Ifnlr1 on intestinal epithelial cells is critical to the antiviral effects of interferon lambda against norovirus and reovirus. J. Virol. 91 (2017), 1–14.
48. Nice, T.J., et al. Interferon lambda cures persistent murine norovirus infection in the absence of adaptive immunity. Science 347 (2015), 269–273.
49. Drummond, C.G., et al. Enteroviruses infect human enteroids and induce antiviral signaling in a cell lineage-specific manner. Proc. Natl. Acad. Sci. U. S. A. 114 (2017), 1672–1677.
50. Lanik, W., et al. Stem cell-derived models of viral infections in the gastrointestinal tract. Viruses, 10, 2018, 124.
51. Hakim, M.S., et al. Basal interferon signaling and therapeutic use of interferons in controlling rotavirus infection in human intestinal cells and organoids. Sci. Rep., 8, 2018, 8341.
52. Saxena, K., et al. A paradox of transcriptional and functional innate interferon responses of human intestinal enteroids to enteric virus infection. Proc. Natl. Acad. Sci. U. S. A. 114 (2017), E570–E579.
53. Pervolaraki, K., et al. Type I and type III interferons display different dependency on mitogen-activated protein kinases to mount an antiviral state in the human gut. Front. Immunol., 8, 2017, 459.
54. Mahlakõiv, T., et al. Leukocyte-derived IFN-α/β and epithelial IFN-λ constitute a compartmentalized mucosal defense system that restricts enteric virus infections. PLoS Pathog., 11, 2015, e1004782.
55. Yin, X., et al. Engineering stem cell organoids. Cell Stem Cell 18 (2016), 25–38.
56. Abbott, N.J., et al. Structure and function of the blood–brain barrier. Neurobiol. Dis. 37 (2009), 13–25.
57. Lazear, H.M., et al. Interferon-l restricts West Nile virus neuroinvasion by tightening the blood–brain barrier. Sci. Transl. Med., 7, 2015 284ra59.
58. Daniels, B.P., Klein, R.S., Knocking on closed doors: host interferons dynamically regulate blood–brain barrier function during viral infections of the central nervous system. PLoS Pathog., 11, 2015, e1005096.
59. Douam, F., et al. Type III interferon-mediated signaling is critical for controlling live attenuated yellow fever virus infection in vivo. mBio 8 (2017), 1–22.
60. Bramley, J.C., et al. A three-dimensional cell culture system to model RNA virus infections at the blood–brain barrier. mSphere, 2, 2017 e00206-17.
61. Roberts, R.M., et al. The evolution of the placenta. Reproduction 152 (2016), R179–R189.
62. Maltepe, E., Fisher, S.J., Placenta: the forgotten organ. Annu. Rev. Cell Dev. Biol. 31 (2015), 523–552.
63. Mi, S., et al. Syncytin is captive retroviral envelope protein involved in human placental morphogenesis. Nature 403 (2000), 785–789.
64. Croy, B., et al. The Guide to Investigation of Mouse Pregnancy. 2014, Academic Press.
65. Dupressoir, A., et al. Syncytin-A and syncytin-B, two fusogenic placenta-specific murine envelope genes of retroviral origin conserved in Muridae. Proc. Natl. Acad. Sci. U. S. A. 102 (2005), 725–730.
66. Georgiades, P., et al. Comparative developmental anatomy of the murine and human definitive placentae. Placenta 23 (2002), 3–19.
67. Bayer, A., et al. Type III interferons produced by human placental trophoblasts confer protection against Zika virus infection. Cell Host Microbe 19 (2016), 705–712.
68. Corry, J., et al. Organotypic models of type III interferon-mediated protection from Zika virus infections at the maternal–fetal interface. Proc. Natl. Acad. Sci. U. S. A. 114 (2017), 9433–9438.
69. Bayer, A., et al. Human trophoblasts confer resistance to viruses implicated in perinatal infection. Am. J. Obstet. Gynecol. 212 (2015), 71e1–71e8.
70. Delorme-Axford, E., et al. Human placental trophoblasts confer viral resistance to recipient cells. Proc. Natl. Acad. Sci. U. S. A. 110 (2013), 12048–12053.
71. McConkey, C.A., et al. A three-dimensional culture system recapitulates placental syncytiotrophoblast development and microbial resistance. Sci. Adv. 2 (2016), 1–9.
72. Jagger, B.W., et al. Gestational stage and IFN-λ signaling regulate ZIKV infection in utero. Cell Host Microbe 22 (2017), 366–376.
73. Chen, J., et al. Outcomes of congenital Zika disease depend on timing of infection and maternal–fetal interferon action. Cell Rep. 21 (2017), 1588–1599.
74. Yockey, L.J., et al. Type I interferons instigate fetal demise after Zika virus infection. Sci. Immunol., 3, 2018 eaao1680.
75. Crow, Y.J., Type I interferonopathies: a novel set of inborn errors of immunity. Ann. N. Y. Acad. Sci. 1238 (2011), 91–98.
76. Meuwissen, M.E.C., et al. Human USP18 deficiency underlies type 1 interferonopathy leading to severe pseudo-TORCH syndrome. J. Exp. Med. 213 (2016), 1163–1174.
77. Andrade, D., et al. Interferon-α and angiogenic dysregulation in pregnant lupus patients who develop preeclampsia. Arthritis Rheumatol. 67 (2015), 977–987.